Browse All

Current Filters

CLEAR FILTER x

TITLE

Longer-term (Up to 6 Years) Efficacy of Ofatumumab in People with Recently Diagnosed and Treatment-naive Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Hauser, Stephen   Bar-Or, Amit   Gold, Ralf   Montalban, Xavier   Cohen, Jeffrey   Robertson, Derrick   Hersh, Carrie   Naismith, Robert   Deiva, Kumaran   Bhatt, Alit   Fu, Haoyi   Boer, Ibolya   Meuth, Sven   Cross, Anne   Gärtner, Jutta   Kappos, Ludwig   

Session Name:S31: Multiple Sclerosis: Therapeutics and Clinical Decision Making  

Topic:Multiple Sclerosis  

Program Number:S31.003  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma, USA, Oklahoma City, OK  UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, California, USA, San Francisco, CA  Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA, Philadelphia, PA  Department of Neurology, Katholisches Klinikum Bochum, Ruhr-Universität Bochum, Bochum, Germany, Bochum, Germany  Department of Neurology Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH  Multiple Sclerosis Division, Department of Neurology, University of South Florida, Tampa, Florida, USA, Tampa, FL  Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, United States, Las Vegas, NV  Department of Neurology, Washington University School of Medicine, Saint Louis, Missouri, USA, Saint Louis, MO  Department of Pediatric Neurology, University Hospitals Paris Saclay, Hôpital Bicêtre, National Reference Center for Rare Inflammatory Brain and Spinal Diseases, Le Kremlin Bicêtre, France, Le Kremlin Bicêtre, France  Novartis Healthcare Pvt. Ltd., Hyderabad, India, Hyderabad, India  Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, East Hanover, NJ  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  Department of Neurology, Medical Faculty, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany, Duesseldorf, Germany  Department of Neurology, Section of Neuroimmunology, Washington University School of Medicine, Saint Louis, Missouri, USA, Clayton, MO  Department of Paediatrics and Adolescent Medicine, Division of Paediatric Neurology, University Medical Centre Göttingen, Georg August University Göttingen, Göttingen, Germany, Göttingen, Germany  Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, Departments of Head, Organs, Spine and Neuromedicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland, Basel, Switzerland  

Safety and Efficacy of Ozanimod in Patients with Early Relapsing Multiple Sclerosis: 1-year Analysis of the ENLIGHTEN Study

Author:Naismith, Robert   Zivadinov, Robert   Morrow, Sarah   Bass, Ann   Obeidat, Ahmed   Riser, Emily   Wray, Sibyl   Cristofanilli, Massimiliano   Riolo, Jon   Thorpe, Andrew   Chaudhry, Burhan   Mohiuddin, Kamran   Cheng, Chun-Yen   DeLuca, John   

Session Name:P10: Multiple Sclerosis: Clinical Trials and Therapeutics (including Safety) 3  

Topic:Multiple Sclerosis  

Program Number:P10.014  

Author Institution:Washington University School of Medicine, St Louis, Missouri, Saint Louis, MO  Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, Buffalo, NY  London Health Sciences Centre, University Hospital, University of Western Ontario, London, Ontario, Canada, and Department of Clinical Neurological Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, London, ON, Canada  Neurology Center of San Antonio, San Antonio, Texas, San Antonio, TX  Department of Neurology, The Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, WI  Alabama Neurology Associates, Birmingham, Alabama, Birmingham, AL  Hope Neurology MS Center, Knoxville, Tennessee, Knoxville, TN  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey, Amherst, NY  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ  

Brain Volume Changes Over 1 Year in Ozanimod-treated Patients with Early-relapsing Multiple Sclerosis: An Interim Analysis of the ENLIGHTEN Study

Author:Zivadinov, Robert   Naismith, Robert   Morrow, Sarah   Bass, Ann   Obeidat, Ahmed   Riser, Emily   Wray, Sibyl   Riolo, Jon   Chaudhry, Burhan   Thorpe, Andrew   Cheng, Chun-Yen   DeLuca, John   

Session Name:P11: Multiple Sclerosis: Epidemiology and Neuroimaging  

Topic:Multiple Sclerosis  

Program Number:P11.017  

Author Institution:Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, New York, Buffalo, NY  Washington University School of Medicine, St Louis, Missouri, Saint Louis, MO  London Health Sciences Centre, University Hospital, University of Western Ontario, London, Ontario, Canada, and Department of Clinical Neurological Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, London, ON, Canada  Neurology Center of San Antonio, San Antonio, Texas, San Antonio, TX  Medical College of Wisconsin, Milwaukee, Wisconsin, Milwaukee, WI  Alabama Neurology Associates, Birmingham, Alabama, Birmingham, AL  Hope Neurology MS Center, Knoxville, Tennessee, Knoxville, TN  Bristol Myers Squibb, Princeton, New Jersey, Princeton, NJ  Bristol Myers Squibb, Princeton, New Jersey , Princeton, NJ  Kessler Foundation, West Orange, New Jersey, and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers - New Jersey Medical School, Newark, New Jersey, West Orange, NJ